Analysts think MBRX stock price could increase by 1254%
Aug 08, 2024, 6:25 AM
10.18%
What does MBRX do
Moleculin Biotech, Inc., a clinical stage pharmaceutical company based in Houston, Texas, specializes in developing drugs for tumors and viruses, employing 15 people since its 2016 IPO. The firm focuses on three core technologies, Annamycin, WP1066, and WP1122 portfolios, with six drug candidates, including WP1066 for multiple oncogenic targets and Annamycin for leukemia and sarcoma treatment.
5 analysts think MBRX stock price will increase by 1253.98%. The current median analyst target is $30.60 compared to a current stock price of $2.26. The lowest analysts target is $20.20 and the highest analyst target is $47.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
